These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
231 related articles for article (PubMed ID: 29097932)
21. Theranostic Perspectives in Prostate Cancer with the Gastrin-Releasing Peptide Receptor Antagonist NeoBOMB1: Preclinical and First Clinical Results. Nock BA; Kaloudi A; Lymperis E; Giarika A; Kulkarni HR; Klette I; Singh A; Krenning EP; de Jong M; Maina T; Baum RP J Nucl Med; 2017 Jan; 58(1):75-80. PubMed ID: 27493272 [TBL] [Abstract][Full Text] [Related]
22. GRPR-selective PET imaging of prostate cancer using [(18)F]-lanthionine-bombesin analogs. Carlucci G; Kuipers A; Ananias HJ; de Paula Faria D; Dierckx RA; Helfrich W; Rink R; Moll GN; de Jong IJ; Elsinga PH Peptides; 2015 May; 67():45-54. PubMed ID: 25797109 [TBL] [Abstract][Full Text] [Related]
23. Preclinical and first clinical experience with the gastrin-releasing peptide receptor-antagonist [⁶⁸Ga]SB3 and PET/CT. Maina T; Bergsma H; Kulkarni HR; Mueller D; Charalambidis D; Krenning EP; Nock BA; de Jong M; Baum RP Eur J Nucl Med Mol Imaging; 2016 May; 43(5):964-973. PubMed ID: 26631238 [TBL] [Abstract][Full Text] [Related]
24. Impact of dianionic and dicationic linkers on tumor uptake and biodistribution of [ Mansour N; Dumulon-Perreault V; Ait-Mohand S; Paquette M; Lecomte R; Guérin B J Labelled Comp Radiopharm; 2017 Apr; 60(4):200-212. PubMed ID: 28129446 [TBL] [Abstract][Full Text] [Related]
25. PET Using a GRPR Antagonist Zhang J; Niu G; Fan X; Lang L; Hou G; Chen L; Wu H; Zhu Z; Li F; Chen X J Nucl Med; 2018 Jun; 59(6):922-928. PubMed ID: 29123014 [TBL] [Abstract][Full Text] [Related]
26. Bispecific GRPR-Antagonistic Anti-PSMA/GRPR Heterodimer for PET and SPECT Diagnostic Imaging of Prostate Cancer. Mitran B; Varasteh Z; Abouzayed A; Rinne SS; Puuvuori E; De Rosa M; Larhed M; Tolmachev V; Orlova A; Rosenström U Cancers (Basel); 2019 Sep; 11(9):. PubMed ID: 31540122 [TBL] [Abstract][Full Text] [Related]
27. Copper-64 Labeled Macrobicyclic Sarcophagine Coupled to a GRP Receptor Antagonist Shows Great Promise for PET Imaging of Prostate Cancer. Gourni E; Del Pozzo L; Kheirallah E; Smerling C; Waser B; Reubi JC; Paterson BM; Donnelly PS; Meyer PT; Maecke HR Mol Pharm; 2015 Aug; 12(8):2781-90. PubMed ID: 26132879 [TBL] [Abstract][Full Text] [Related]
28. Preclinical Evaluation of Abouzayed A; Rinne SS; Sabahnoo H; Sörensen J; Chernov V; Tolmachev V; Orlova A Pharmaceutics; 2021 Jan; 13(2):. PubMed ID: 33573232 [TBL] [Abstract][Full Text] [Related]
29. In vitro and in vivo evaluation of a 64Cu-labeled NOTA-Bn-SCN-Aoc-bombesin analogue in gastrin-releasing peptide receptor expressing prostate cancer. Craft JM; De Silva RA; Lears KA; Andrews R; Liang K; Achilefu S; Rogers BE Nucl Med Biol; 2012 Jul; 39(5):609-16. PubMed ID: 22261146 [TBL] [Abstract][Full Text] [Related]
30. Bombesin antagonist-based radioligands for translational nuclear imaging of gastrin-releasing peptide receptor-positive tumors. Abiraj K; Mansi R; Tamma ML; Fani M; Forrer F; Nicolas G; Cescato R; Reubi JC; Maecke HR J Nucl Med; 2011 Dec; 52(12):1970-8. PubMed ID: 22080443 [TBL] [Abstract][Full Text] [Related]
31. Molecular imaging of gastrin-releasing peptide receptor-positive tumors in mice using 64Cu- and 86Y-DOTA-(Pro1,Tyr4)-bombesin(1-14). Biddlecombe GB; Rogers BE; de Visser M; Parry JJ; de Jong M; Erion JL; Lewis JS Bioconjug Chem; 2007; 18(3):724-30. PubMed ID: 17378600 [TBL] [Abstract][Full Text] [Related]
32. N-terminal modifications improve the receptor affinity and pharmacokinetics of radiolabeled peptidic gastrin-releasing peptide receptor antagonists: examples of 68Ga- and 64Cu-labeled peptides for PET imaging. Gourni E; Mansi R; Jamous M; Waser B; Smerling C; Burian A; Buchegger F; Reubi JC; Maecke HR J Nucl Med; 2014 Oct; 55(10):1719-25. PubMed ID: 25146125 [TBL] [Abstract][Full Text] [Related]
33. Synthesis, radiolabeling, and evaluation of gastrin releasing peptide receptor antagonist Satpati D; Vats K; Sharma R; Kameswaran M; Sarma HD; Dash A J Labelled Comp Radiopharm; 2019 Oct; 62(12):843-849. PubMed ID: 31378967 [TBL] [Abstract][Full Text] [Related]
34. Gastrin-releasing peptide receptor as theranostic target in estrogen-receptor positive breast cancer: A preclinical study of the theranostic pair [ Baun C; Olsen BB; Alves CML; Ditzel HJ; Terp M; Hildebrandt MG; Poulsen CA; Gé LG; Gammelsrød VS; Orlova A; Dam JH; Thisgaard H Nucl Med Biol; 2024; 138-139():108961. PubMed ID: 39357076 [TBL] [Abstract][Full Text] [Related]
35. 18F-labeled bombesin analog for specific and effective targeting of prostate tumors expressing gastrin-releasing peptide receptors. Honer M; Mu L; Stellfeld T; Graham K; Martic M; Fischer CR; Lehmann L; Schubiger PA; Ametamey SM; Dinkelborg L; Srinivasan A; Borkowski S J Nucl Med; 2011 Feb; 52(2):270-8. PubMed ID: 21233180 [TBL] [Abstract][Full Text] [Related]
36. Preclinical pharmacokinetic, biodistribution, imaging and therapeutic efficacy of (177)Lu-Labeled glycated bombesin analogue for gastrin-releasing peptide receptor-positive prostate tumor targeting. Lim JC; Cho EH; Kim JJ; Choi SM; Lee SY; Nam SS; Park UJ; Park SH Nucl Med Biol; 2015 Mar; 42(3):234-41. PubMed ID: 25498002 [TBL] [Abstract][Full Text] [Related]
37. Synthesis, preclinical, and initial clinical evaluation of integrin α Wen X; Wang R; Xu P; Shi M; Shang Q; Zeng X; Zeng X; Liu J; Wang X; Zhu Z; Guo Z; Chen X; Zhang J Eur J Nucl Med Mol Imaging; 2024 Jun; 51(7):2023-2035. PubMed ID: 38376806 [TBL] [Abstract][Full Text] [Related]